Chargement en cours...
Efficacy of Anti-Mesothelin Immunotoxin RG7787 plus nab-Paclitaxel against Mesothelioma Patient Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
PURPOSE: Evaluate anti-tumor efficacy of the reduced immunogenicity anti-mesothelin immunotoxin RG7787 plus nab-Paclitaxel against primary mesothelioma cell lines and tumor xenografts and utility of mesothelin as a biomarker of tumor response. EXPERIMENTAL DESIGN: Early passage human malignant mesot...
Enregistré dans:
| Publié dans: | Clin Cancer Res |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5352557/ https://ncbi.nlm.nih.gov/pubmed/27635089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1667 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|